Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been assigned an average recommendation of "Buy" from the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $16.43.
Several equities research analysts have issued reports on LXEO shares. Chardan Capital upgraded Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Leerink Partners reaffirmed an "outperform" rating and set a $15.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, September 23rd. Raymond James Financial reiterated a "strong-buy" rating on shares of Lexeo Therapeutics in a report on Monday. Wall Street Zen downgraded shares of Lexeo Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexeo Therapeutics in a research note on Wednesday, November 11th.
Get Our Latest Report on LXEO
Lexeo Therapeutics Stock Down 11.5%
LXEO opened at $2.86 on Wednesday. Lexeo Therapeutics has a 12 month low of $2.55 and a 12 month high of $10.99. The company has a fifty day simple moving average of $3.31 and a 200 day simple moving average of $4.96. The stock has a market cap of $234.66 million, a P/E ratio of -2.29 and a beta of 1.64.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.11). On average, equities research analysts expect that Lexeo Therapeutics will post -1.22 earnings per share for the current fiscal year.
Latest Lexeo Therapeutics News
Here's some of the latest news about LXEO:
- Positive Sentiment: Lexeo said the FDA is open to guideline-defined non-sustained ventricular tachycardia as a potential primary surrogate endpoint for accelerated approval. The company plans to begin a pivotal study in late 2027, offering a possible development path, though approval is not assured. Benzinga report
- Positive Sentiment: Lexeo reported $219.1 million in cash, cash equivalents and investments, which it expects to fund operations into 2028. Separate coverage said the trial data prompted price-target increases from analysts. Analyst price-target report
- Negative Sentiment: Third-quarter adjusted loss was $0.43 per share, wider than analysts’ $0.32-per-share loss estimate. This earnings shortfall may weigh on sentiment, although the clinical update was the larger focus of recent coverage. Earnings report
Institutional Investors Weigh In On Lexeo Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Lexeo Therapeutics in the second quarter valued at about $26,717,000. Montanova Capital LLC boosted its position in shares of Lexeo Therapeutics by 410.7% during the second quarter. Montanova Capital LLC now owns 6,384,200 shares of the company's stock worth $29,718,000 after buying an additional 5,134,200 shares during the period. Jupiter Topco LLC acquired a new position in shares of Lexeo Therapeutics during the second quarter worth about $18,409,000. Affinity Asset Advisors LLC boosted its position in shares of Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company's stock worth $28,988,000 after buying an additional 1,850,211 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Lexeo Therapeutics during the second quarter worth about $7,289,000. 60.67% of the stock is owned by institutional investors.
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company's investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.